You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

19 Results
Guidelines and Advice
Status: Archived
ID: 22-2-1
Jun 2014
Guidelines and Advice
Status: Archived
ID: 22-2-2
Jun 2014
Guidelines and Advice
Status: Archived
ID: 22-2-3
Jun 2014
Guidelines and Advice
Status: Archived
ID: 22-2-4
Jun 2014
Guidelines and Advice
Status: Archived
ID: 22-2-5
Jun 2014
Guidelines and Advice
Status: Archived
ID: 22-2-6
Jun 2014
Guidelines and Advice
Status: Archived
ID: 22-2-7
Jun 2014
Guidelines and Advice
Status: Archived
ID: 22-2-8
Jun 2014
Guidelines and Advice
Status: Archived
ID: 22-2-9
Jun 2014
Guidelines and Advice
Status: Archived
ID: 22-2-10
Jun 2014
Guidelines and Advice
Status: Archived
ID: 22-2-M
Jun 2014
Regimen
Cancer Type:
Hematologic
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
ODB - General Benefit
    prednisone
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Bortezomib - Previously Untreated Transplant Ineligible Mantle Cell Lymphoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
prednisone,
bortezomib,
riTUXimab,
DOXOrubicin,
cyclophosphamide,
riTUXimab (subcut)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2023

Pages